Platelet Reactivity Units (P2Y12)
| Label Mnemonic: | PRU |
| Epic code: | LAB8075 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Hematology
6240 RCP
356-3527
6240 RCP
356-3527
Specimen(s):
Whole Blood
Specimen
Instructions:
Must be drawn in special sodium citrate tubes. Call Tech
Services (356-3527) for collection kit.
Collection Medium:
) |
| Special Coagulation Tube |
Minimum:
Must be collected in a (2 mL) special collection tube.
Rejection Criteria:
If specimen is over 4 hours old and not drawn in special collection
tubes.
Delivery Instructions:
Must be hand-delivered to laboratory within 2 hours
of collection; specimen cannot be sent using pneumatic
tube system. Keep at room temperature.Testing Schedule:
24 hrs/day, 7 days a week, including holidays.
Turn Around
Time:
1 hour (upon receipt in laboratory)
Reference Range:
182-335 RU
Interpretive Data:
Values less than 182 PRU suggest evidence of a P2Y12 inhibitor
effect.
Patients who have been treated with Glycoprotein IIb/IIIa inhibitors should not be tested until platelet function has recovered. This time period is approximately 14 days after discontinuation of abciximab (ReoPro) and up to 48 hours after discontinuation of eptifibatide (Integrilin) and tirofiban (Aggrastat).
Patients who have been treated with Glycoprotein IIb/IIIa inhibitors should not be tested until platelet function has recovered. This time period is approximately 14 days after discontinuation of abciximab (ReoPro) and up to 48 hours after discontinuation of eptifibatide (Integrilin) and tirofiban (Aggrastat).
Comments:
The following drugs are P2Y12 inhibitors: Clopidogrel (Plavix),
Ticlopidine (Ticlid), Prasugrel (Effient), and Ticagrelor (Brilinta).
Test
Limitations:
Improper sample collection (platelet activation) or patient's exposure
to GPIIb/IIIa inhibitors within: 48 hours of eptifibatide or 14 days
of abciximab.
Test performance has only been validated for hematocrit values between 33-52% and platelet counts between 119-502 K/MM3. Patients with hematocrits or platelet counts outside of these ranges may generate unreliable results.
Test performance has only been validated for hematocrit values between 33-52% and platelet counts between 119-502 K/MM3. Patients with hematocrits or platelet counts outside of these ranges may generate unreliable results.
Methodology:
The VerifyNow system incorporates ADP induced aggregation - to
determine extent of platelet aggregation in the presence of P2Y12
inhibitors.
CPT Code:
85576